HPC is changing the landscape of cancer research. Hear Argonne experts and partner panelists discuss HPC’s impact on this critical work at two Computational Approaches for Cancer Workshop talks, Anti-Cancer Drug Response Prediction on Patient-Derived Xenografts: Learning from Extremely Limited Data and Cross-HPO: Optimizing Neural Networks for Cancer Drug Response Using Hyperparameter Tuning on Multiple Pharmacogenomic Datasets.